Literature DB >> 21233181

Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.

Ara H Rostomian1, Cindee Madison, Gil D Rabinovici, William J Jagust.   

Abstract

UNLABELLED: The availability of new PET ligands offers the potential to measure fibrillar β-amyloid in the brain. Nevertheless, physiologic information in the form of perfusion or metabolism may still be useful in differentiating causes of dementia during life. In this study, we investigated whether early (11)C-Pittsburgh compound B ((11)C-PIB) PET frames (perfusion (11)C-PIB [pPIB]) could provide information equivalent to blood flow and metabolism. First, we assessed the similarity of pPIB and (18)F-FDG PET images in a test cohort with various clinical diagnoses (n = 10), and then we validated the results in a cohort of patients with Alzheimer disease (AD) (n = 42; mean age ± SD, 66.6 ± 10.6 y; mean Mini-Mental State Examination [MMSE] score ± SD, 22.2 ± 6.0) or frontotemporal lobar degeneration (FTLD) (n = 31; age ± SD, 63.9 ± 7.1 y, mean MMSE score ± SD, 23.8 ± 6.7).
METHODS: To identify the (11)C-PIB frames best representing perfusion, we ran on a test cohort an iterative algorithm, including generating normalized (cerebellar reference) perfusion pPIB images across variable frame ranges and calculating Pearson R values of the sum of these pPIB frames with the sum of all (18)F-FDG frames (cerebellar normalized) for all brain tissue voxels. Once this perfusion frame range was determined on the test cohort, it was then validated on an extended cohort and the power of pPIB in differential diagnosis was compared with (18)F-FDG by performing a logistic regression of regions-of-interest tracer measure (pPIB or (18)F-FDG) versus diagnosis.
RESULTS: A 7-min window, corresponding to minutes 1-8 (frames 5-15), produced the highest voxelwise correlation between (18)F-FDG and pPIB (R = 0.78 ± 0.05). This pPIB frame range was further validated on the extended AD and FTLD cohort across 12 regions of interest (R = 0.91 ± 0.09). A logistic model using pPIB was able to classify 90.5% of the AD and 83.9% of the FTLD patients correctly. Using (18)F-FDG, we correctly classified 88.1% of AD and 83.9% of FTLD patients. The temporal pole and temporal neocortex were significant discriminators (P < 0.05) in both models, whereas in the model with pPIB the frontal region was also significant.
CONCLUSION: The high correlation between pPIB and (18)F-FDG measures and their comparable performance in differential diagnosis are promising in providing functional information using (11)C-PIB PET data. This approach could be useful, obviating (18)F-FDG scans when longer-lived amyloid imaging agents become available.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233181      PMCID: PMC3166243          DOI: 10.2967/jnumed.110.082057

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.

Authors:  Joseph A Maldjian; Paul J Laurienti; Robert A Kraft; Jonathan H Burdette
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

2.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

3.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

4.  Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.

Authors:  Ansgar J Furst; Gil D Rabinovici; Ara H Rostomian; Tyler Steed; Adi Alkalay; Caroline Racine; Bruce L Miller; William J Jagust
Journal:  Neurobiol Aging       Date:  2010-04-24       Impact factor: 4.673

Review 5.  PET imaging of amyloid in Alzheimer's disease.

Authors:  Agneta Nordberg
Journal:  Lancet Neurol       Date:  2004-09       Impact factor: 44.182

6.  What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

Authors:  W Jagust; B Reed; D Mungas; W Ellis; C Decarli
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

7.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

8.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.

Authors:  G D Rabinovici; A J Furst; J P O'Neil; C A Racine; E C Mormino; S L Baker; S Chetty; P Patel; T A Pagliaro; W E Klunk; C A Mathis; H J Rosen; B L Miller; W J Jagust
Journal:  Neurology       Date:  2007-04-10       Impact factor: 9.910

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

10.  Unidirectional Influx and Net Accumulation of PIB.

Authors:  Gunnar Blomquist; Henry Engler; Agneta Nordberg; Anna Ringheim; Anders Wall; Anton Forsberg; Sergio Estrada; Pernilla Frändberg; Gunnar Antoni; Bengt Långström
Journal:  Open Neuroimag J       Date:  2008-11-13
View more
  32 in total

1.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.

Authors:  Ing-Tsung Hsiao; Chin-Chang Huang; Chia-Ju Hsieh; Wen-Chun Hsu; Shiaw-Pyng Wey; Tzu-Chen Yen; Mei-Ping Kung; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

Review 2.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

3.  A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5.

Authors:  Geoffrey Warnock; Michael Sommerauer; Linjing Mu; Gloria Pla Gonzalez; Susanne Geistlich; Valerie Treyer; Roger Schibli; Alfred Buck; Stefanie D Krämer; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

4.  Analysis of early phase [11C]BF-227 PET, and its application for anatomical standardization of late-phase images for 3D-SSP analysis.

Authors:  Tomohiro Kaneta; Nobuyuki Okamura; Akira Arai; Kentaro Takanami; Katsutoshi Furukawa; Manabu Tashiro; Shozo Furumoto; Ren Iwata; Shoki Takahashi; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo
Journal:  Jpn J Radiol       Date:  2014-01-10       Impact factor: 2.374

5.  Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease.

Authors:  Elena Rodriguez-Vieitez; Antoine Leuzy; Konstantinos Chiotis; Laure Saint-Aubert; Anders Wall; Agneta Nordberg
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

6.  Dual-phase amyloid PET: hitting two birds with one stone.

Authors:  Garibotto Valentina; Morbelli Silvia; Pagani Marco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-23       Impact factor: 9.236

7.  In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study.

Authors:  Alexander Frizell Santillo; Juan Pablo Gambini; Lars Lannfelt; Bengt Långström; Luohija Ulla-Marja; Lena Kilander; Henry Engler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

8.  Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging.

Authors:  Murat Bilgel; Lori Beason-Held; Yang An; Yun Zhou; Dean F Wong; Susan M Resnick
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-12       Impact factor: 6.200

9.  Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.

Authors:  Liping Fu; Linwen Liu; Jinming Zhang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

10.  Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.

Authors:  Solveig Tiepolt; Swen Hesse; Marianne Patt; Julia Luthardt; Matthias L Schroeter; Karl-Titus Hoffmann; David Weise; Hermann-Josef Gertz; Osama Sabri; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.